Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma.Materials and methods Thi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2024-12-01
Serie:	Annals of Medicine
Soggetti:	Long-term access program mepolizumab open-label extension safety severe asthma with an eosinophilic phenotype
Accesso online:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2417184
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!